Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit - Reuters

Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit  Reuters

Novo Nordisk to Sell Weight-Loss Drugs Through Hims & Hers - WSJ

Novo Nordisk to Sell Weight-Loss Drugs Through Hims & Hers  WSJ

Hims shares shoot up after weight-loss drug deal with Novo Nordisk

US telehealth group and Danish drugmaker have been in dispute over copycat medicines

Hims & Hers shares surge 50% after Novo Nordisk drops patent infringement case over compounded weight loss drugs

Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would sell Novo's branded medicines.

Hims & Hers stock rockets on reported end to Novo Nordisk weight-loss drug dispute

Hims & Hers shares jumped nearly 50% in premarket trade on Monday after a report it has ended a dispute with Novo Nordisk by striking a partnership with the Danish drug giant.

By Steve Goldstein

Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy?

Hims & Hers Health boosted at Citi on Novo Nordisk partnership

Hims & Hers Erupts In Epic Squeeze As Novo Nordisk Ends GLP-1 Feud

Hims & Hers Erupts In Epic Squeeze As Novo Nordisk Ends GLP-1 Feud Novo Nordisk confirmed Monday morning that its months-long GLP-1 feud with telehealth firm Hims & Hers Health has, at least for now, been put on ice, with the Danish drugmaker set to sell Wegovy and Ozempic through HIMS' platform by the end of the month. The feud's end was first reported by Bloomberg late Friday and has sparked a panic short squeeze in heavily shorted HIMS shares in New York premarket trading. Bl...

By Tyler Durden